Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone
Retrieved on:
Monday, August 9, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, AbbVie, Neurodegeneration, Fibrosis, Laboratory, IP Group, Dementia, Kidney disease, Therapy, Sofinnova, Lists of diseases, University, Drug development, DUB, Enzyme, Patient, NYSE, Dub, LinkedIn, Degenerative disease, Neuroscience, Death, Virology, Brain, Research, YouTube, Protein, Drug discovery, Gastroenterology, Instagram, Twitter, Company, Pharmaceutical industry, Mission Therapeutics, AbbVie, MISSION THERAPEUTICS, ABBVIE
In the second major milestone of the Companies research and preclinical development collaboration, AbbVie has nominated two DUB targets to progress to the next stage of drug discovery.
Key Points:
- In the second major milestone of the Companies research and preclinical development collaboration, AbbVie has nominated two DUB targets to progress to the next stage of drug discovery.
- This selection follows supportive data from in vitro and in vivo Alzheimers and Parkinsons disease models.
- As a result of the nomination, Mission will receive a milestone payment of $20 million from AbbVie.
- Alzheimers and Parkinsons diseases are the most common neurological disorders worldwide, with over 50 million people living with dementia and Alzheimers disease, and 10 million more with Parkinsons.